Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
Fierce Biotech
Thu, 12/22/22 - 11:05 am
Biogen
Eisai
Alzheimer's disease
clinical trials
patient deaths
lecanemab
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Endpoints
Wed, 12/21/22 - 11:31 am
Biogen
FDA
Alzheimer's disease
CMS
clinical trials
Roche takes over development of Biogen-partnered lymphoma drug
BioPharma Dive
Tue, 12/20/22 - 11:11 am
Roche
Biogen
lymphoma
glofitamab
Biogen's ALS Drug Tofersen Filing Accepted in Europe
Zacks.com
Tue, 12/6/22 - 10:48 am
Biogen
ALS
EMA
Europe
tofersen
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Thu, 12/1/22 - 07:10 pm
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
CTAD 2022 – lecanemab data hold up, with a big but
EP Vantage
Thu, 12/1/22 - 07:01 pm
Biogen
Eisai
Alzheimer's disease
CTAD
lecanemab
clinical trials
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
BioPharma Dive
Tue, 11/29/22 - 10:58 pm
Biogen
Eisai
Alzheimer's disease
lecanemab
Eisai, Biogen rocked by 2nd lecanemab death report ahead of Alzheimer's data reveal
Fierce Biotech
Mon, 11/28/22 - 07:51 pm
Biogen
Eisai
clinical trials
patient death
lecanemab
Alzheimer's disease
Roche Failure Leaves Industry Reassessing Alzheimer's Space
BioSpace
Wed, 11/16/22 - 10:45 am
Roche
Alzheimer's disease
gantenerumab
Biogen
Cassava Sciences
Eli Lilly
Biogen appoints ex-Sanofi chief Christopher Viehbacher as CEO
Medical Marketing and Media
Thu, 11/10/22 - 10:51 am
Biogen
Pharma CEOs
Christopher Viehbacher
Chris Viehbacher
J&J vet Mammen wanted board influence to be Biogen's next CEO, but chairman said no
Fierce Pharma
Tue, 11/8/22 - 10:43 pm
JNJ
Biogen
Pharma CEOs
Mathai Mammen
Biogen, BioAge and PTC Present Novel MoAs in Neurodegenerative Diseases
BioSpace
Mon, 11/7/22 - 10:52 am
neurodegenerative disease
Biogen
BioAge Labs
PTC Therapeutics
MS Drug Advances from Merck, BMS and More Showcased at ECTRIMS Conference
BioSpace
Wed, 10/26/22 - 06:51 pm
Merck
Biogen
Bristol Myers Squibb
MS
multiple sclerosis
ECTRIMS
Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates
Endpoints
Tue, 10/25/22 - 11:05 am
Biogen
earnings
Alzheimer's disease
ALS
tofersen
lecanemab
Where Will Biogen Be in 5 Years?
Motley Fool
Thu, 10/20/22 - 10:39 am
Biogen
Aduhelm
lecanemab
Alzheimer's disease
M&A
Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months
Fierce Biotech
Mon, 10/17/22 - 10:53 am
Biogen
tofersen
FDA
ALS
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Fierce Biotech
Mon, 10/17/22 - 10:39 am
SAGE Therapeutics
Biogen
zuranolone
postpartum depression
clinical trials
4 Biotech Stocks With Huge Incoming Catalysts
Motley Fool
Wed, 10/12/22 - 11:03 am
FDA
Biogen
Eisai
Alzheimer's disease
Gilead Sciences
HIV
Mirati Therapeutics
lung cancer
lecanemab
lenacapavir
adagrasib
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »